Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

Category	Detail
Condition	Early COVID-19 infection
Key Mechanisms	Monoclonal antibodies (tixagevimab/cilgavimab) target SARS-CoV-2, rapidly eliminating culturable virus and minimizing resistance emergence
Target Population	Nonhospitalized adults with mild-to-moderate COVID-19, including those ineligible for oral antivirals
Care Setting	Outpatient clinics and community-based settings

Both intramuscular (IM) and intravenous (IV) administration of tixagevimab/cilgavimab achieve rapid clearance of culturable SARS-CoV-2.
IM administration offers a scalable, practical alternative to IV infusion without compromising virologic efficacy.
Minimal emergence of resistance-associated mutations observed with combination monoclonal antibody therapy.

Confirm SARS-CoV-2 infection with detectable nasopharyngeal RNA within 10 days of symptom onset.

Administer tixagevimab/cilgavimab monoclonal antibodies via IM or IV routes in early COVID-19 to rapidly reduce culturable virus.
Consider IM delivery to facilitate scalable treatment deployment in outpatient or community settings.

Monitor viral RNA levels and viral culture status to assess treatment efficacy.
Sequence SARS-CoV-2 spike gene to detect emergent resistance mutations during and after therapy.

Resistance emergence is infrequent with combination monoclonal antibody therapy but should be monitored.
IV administration requires infusion infrastructure and trained personnel; IM administration reduces these logistical risks.

Nonhospitalized adults with mild-to-moderate COVID-19, including those at risk for severe disease and ineligible for oral antivirals.

IM administration achieves systemic exposure and virologic outcomes comparable to IV infusion, supporting its use as a practical alternative.

Use combination monoclonal antibody therapy (tixagevimab/cilgavimab) early in COVID-19 to maximize viral clearance.
Prefer IM administration when feasible to enhance treatment scalability and accessibility.
Employ viral culture assays as sensitive early endpoints to evaluate antiviral efficacy beyond RNA quantification.
Conduct spike gene sequencing to monitor for resistance mutations during treatment.

Clinical Scorecard: Swift Clearance of Culturable SARS-CoV-2 Through Intramuscular or Intravenous Delivery of Antiviral Monoclonal Antibodies